Illumina, Inc.

Global Companion Diagnostics Research Report 2024-2029: $13.5+ Billion Market Analysis by Assays, Kits, Reagents, System, Software & Services, PCR, NGS, ISH, IHC - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Maggio 13, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, NGS, ChromeOS, Assay, Region, USD, ISH, Danaher Corporation, Sysmex Corporation, Software, Government, Colorectal cancer, Pulse, Abbott Laboratories, Drug development, ICON PLC, Lung, Cancer, Growth, Research, CVD, Incidence, Biomarker, IHC, BioMérieux, Agilent Technologies, Illumina, Inc., PCR

The global companion diagnostics market is projected to reach USD 13.6 billion by 2029 from USD 7.5 billion in 2024, at a CAGR of 12.6% during the forecast period.

Key Points: 
  • The global companion diagnostics market is projected to reach USD 13.6 billion by 2029 from USD 7.5 billion in 2024, at a CAGR of 12.6% during the forecast period.
  • The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall companion diagnostics market and its subsegments.
  • Based on end user, the companion diagnostics market is segmented into pharmaceutical & biotechnology companies, reference laboratories, CROs, and other end users.
  • In 2023, pharmaceutical & biotechnology companies stood out as the primary users of companion diagnostics within the market.

Global Prenatal Testing Market Report 2024: Historical Revenue Data for 2021-2022, Estimates for 2023, Forecasts for 2024, and CAGR Projections through 2028 - ResearchAndMarkets.com

Retrieved on: 
Venerdì, Maggio 3, 2024
Baby, Maternity, Health, Consumer, Other Health, Insight, Noninvasive prenatal testing, Pregnancy, DSM-IV codes, Research, Genetic testing, Labcorp, Government, NIPT, Amniocentesis, ESG, Thermo Fisher Scientific, Maternal death, Chromosome, Illumina, Inc., Biomarker

The "Global Prenatal Testing Market 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Prenatal Testing Market 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The scope of the prenatal testing market is extensive and continually evolving, reflecting the dynamic landscape of technologies and methodologies employed to assess fetal health during pregnancy.
  • This market is characterized by its global reach, with varying levels of adoption and accessibility across different regions.
  • The report covers geographic regions in detail, so companies interested in expanding their geographic reach will also find this helpful study.

Sphere Fluidics Appoints Dale Levitzke as Chief Executive Officer

Retrieved on: 
Martedì, Aprile 30, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Health Technology, Lead, Single-cell analysis, Bio-Rad Laboratories, Microfluidics, Marketing, NanoString Technologies, Molecular biology, Genetics, Retirement, IPO, Sphere, Senior, Bachelor of Science, Sphere Fluidics, Acquisition, Synthetic biology, Illumina, Inc., La Trobe University

In his role as CEO, Dale will shape Sphere Fluidics’ future commercial business and progress the Company’s continued global expansion strategy to reach new customers and create value for shareholders.

Key Points: 
  • In his role as CEO, Dale will shape Sphere Fluidics’ future commercial business and progress the Company’s continued global expansion strategy to reach new customers and create value for shareholders.
  • Throughout his career, Dale has focused on supporting early-stage and VC-backed pioneering tools companies and steering them towards global market success.
  • Dr. Frank F. Craig co-founded Sphere Fluidics, alongside Professor Chris Abell and Professor Wilhelm Huck, before becoming CEO in 2010.
  • Dale Levitzke, incoming CEO, Sphere Fluidics, added: “Sphere Fluidics’ picodroplet technology and microfluidics platforms are transforming single cell analysis and isolation capabilities, bringing new possibilities to biopharmaceutical research and development.

United States Liquid Biopsy Market Report 2023 and 2024-2032 Featuring Thermo Fisher Scientific, Roche Diagnostics, Bio-Rad, Biocept, Biocartis, Myriad Genetics, Exact Sciences, NeoGenomics, Quest - ResearchAndMarkets.com

Retrieved on: 
Martedì, Aprile 23, 2024
Biotechnology, Surgery, Health, Genetics, Oncology, Liquid biopsy, Neoplasm, Nucleic acid thermodynamics, FDA, Urine, Breast cancer, CGP, NTRK, Prostate cancer, NIH, Woman, Blood, Entrectinib, Seminal vesicles, Gene, Liquid, Health care, Research, Plasma, Chinese, NGS, DNA, Lung, Incidence, Patient, Circulating tumor DNA, Diagnosis, Illumina, Inc., Biomarker, DCIS, NSCLC, Medical imaging

The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering.
  • The United States Liquid Biopsy Market value is foreseen to be around US$ 3.68 Billion by 2032.
  • These innovations enhance cancer detection and monitoring and propel the United States liquid biopsy market.
  • Breast cancer might stand out as a distinguished concern in the United States liquid biopsy market.

Laboratory Information Management System (LIMS) Market Size to Grow by USD 907.08 million from 2023 to 2027, Market growth at 9.08% CAGR expected during the forecast period, Technavio

Retrieved on: 
Martedì, Marzo 26, 2024
Cloud, PerkinElmer, Laboratory information management system, Informatics, Component, Health, Paperless office, Laboratory, Saas, Automation, Thermo Fisher Scientific, Risk, ROW, ISO 17025, Privacy, Data management, Documentation, Biobank, LIMS, Research, AI, Food, Machine learning, ISO/IEC 17025, Growth, Abbott Laboratories, ERP, Software, Illumina, Inc., Comp, Life, ISO, Hardware

By geography, the global laboratory information management system (lims) market is segmented into North America, Europe, Asia, and Rest of World (ROW).

Key Points: 
  • By geography, the global laboratory information management system (lims) market is segmented into North America, Europe, Asia, and Rest of World (ROW).
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global laboratory information management system (lims) market.
  • Driving Forces in the LIMS Market:
    Stringent compliance and governmental regulations propel the growth of the Laboratory Management System (LIMS) market.
  • Growth of the Laboratory Information Management System (LIMS) Market industry across North America, Europe, Asia, and Rest of World (ROW)
    Gain instant access to 17,000+ market research reports.

Vivani Medical Appoints Daniel Bradbury to its Board of Directors

Retrieved on: 
Mercoledì, Marzo 6, 2024
Biotechnology, Pharmaceutical, Health, Acquisition, Medicine, Illumina, Inc., Obesity, Marketing, Amylin Pharmaceuticals, Audit committee, University, University of Nottingham, Therapy, Management, DSM-IV codes, Bristol Myers Squibb, Vivani, Pharmaceutical industry

Vivani Medical, Inc. (Nasdaq: VANI ) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today announced the appointment of long-time industry veteran Daniel Bradbury to its Board of Directors.

Key Points: 
  • Vivani Medical, Inc. (Nasdaq: VANI ) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today announced the appointment of long-time industry veteran Daniel Bradbury to its Board of Directors.
  • Bradbury serves on the board of directors of Castle Biosciences, Inc. and Equillium, Inc., and several private companies and philanthropic organizations.
  • Bradbury previously served on the board of directors of Biocon Limited, Corcept Therapeutics Inc., Geron Inc., Illumina Inc. and Intercept Pharmaceuticals Inc.
  • In addition to his new role as Board Director, Bradbury will serve on the Audit Committee of the Vivani Medical Board.

Next-Generation Sequencing Emerging Clinical Applications and Global Markets, with Profiles of Leading Players Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies and BGI Genomics - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Febbraio 12, 2024
Biotechnology, Genetics, Health, Agilent Technologies, BGI Group, Genetic disorder, Magnis, Illumina, Inc., DSM-IV codes, Genetic variation, Liquid biopsy, QIAGEN, Genomics, NGS, Marker beacon, Thermo Fisher Scientific, BGI, Fertilisation, Noninvasive prenatal testing, Genome, Informatics, CTC, Research, DNA, Medical device

The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The NGS platform enables companies to expand the menu of disorders/diseases over time after initial launch of a test.
  • The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents, and companies.
  • This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing.

Illumina expands collaboration with Janssen to advance molecular residual disease cancer test

Retrieved on: 
Venerdì, Gennaio 5, 2024
Neoplasm, MRD, Research, Janssen, Disease, DNA, SAN, Janssen Pharmaceuticals, Illumina, Inc., Recurrence, Cancer, Patient, Organization, WGS, Security (finance), Medical imaging

SAN DIEGO, Jan. 5, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has signed an agreement with Janssen Research & Development, LLC (Janssen).

Key Points: 
  • SAN DIEGO, Jan. 5, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has signed an agreement with Janssen Research & Development, LLC (Janssen).
  • This collaboration will be the first relating to the development of Illumina's novel molecular residual disease (MRD) assay, a whole-genome sequencing (WGS) multi-cancer research solution that detects circulating tumor DNA (ctDNA) to better understand the persistence or recurrence of disease following clinical intervention.
  • "Working together with pharma partners like Janssen, we aim to deliver a sensitive, accurate, and easily accessible whole-genome sequencing MRD assay to advance clinical research in oncology."
  • Illumina intends to collaborate with other leaders in pharma to help further develop and expand the utility of its WGS MRD assay.

The Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK, and Novo Nordisk

Retrieved on: 
Giovedì, Gennaio 4, 2024
Drug discovery, Amgen, Probability, AstraZeneca, Data, Health, AGD, Vanderbilt University Medical Center, DNA, Doctor of Philosophy, Illumina, Inc., SAN, Novo Nordisk, VUMC, BMS, Genome, Organization, Bristol Myers Squibb, AbbVie, WGS, Security (finance)

SAN DIEGO, Jan. 4, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced three new members of the Alliance for Genomic Discovery (AGD).

Key Points: 
  • Bristol Myers Squibb (BMS), GSK and Novo Nordisk join founding member organizations AbbVie, Amgen, AstraZeneca, Bayer, and Merck.
  • Together the pharma members will co-fund the whole-genome sequencing (WGS) of 250,000 DNA samples and have access to the resulting data for use in drug discovery and therapeutic development.
  • "This rich dataset will enable the discovery of highly actionable therapeutic targets and improve the speed, probability of success, and efficiency of the discovery and development process."
  • This release contains forward-looking statements that involve risks and uncertainties, including the expectation for lower costs related to the storing and managing of genomic data costs.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Illumina, Inc. (ILMN)

Retrieved on: 
Lunedì, Novembre 20, 2023
Defendant, Suite, Acquisition, GRAIL, Complaint, Illumina, Inc., GPM, Icahn, Court, News, Medical device, Accounting, Cryptocurrency, Reuters, Illumina

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • If you purchased or otherwise acquired Illumina securities during the Class Period, you may move the Court no later than January 9, 2024 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles